The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Use of antihypertensives and the risk of Parkinson disease
Abstract
Background: Recent studies related angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers to possible neuroprotective effects. Little is known about neuroprotection of angiotensin II (AT II) antagonists or beta-blockers. Objective: To explore the association between antihypertensive drug use and the risk of developing a first-time diagnosis of Parkinson disease (PD). Methods: This was a case-control analysis within the UK-based General Practice Research Database. Cases were ≥40 years of age with an incident PD diagnosis between 1994 and 2005. We matched one control to each PD case on age, sex, general practice, index date, and duration of previous history in the database. We assessed antihypertensive drug use by timing and by exposure duration. We calculated ORs using conditional logistic regression, adjusted for body mass index, smoking, and various cardiovascular, metabolic, and psychiatric diseases and dementia. Results: We identified 3,637 cases with a first-time diagnosis of idiopathic PD and an equal number of matched controls. As compared to nonuse of antihypertensive drugs, the adjusted OR for current use of ≥30 prescriptions was 1.08 (95% CI 0.85 to 1.37) for ACE inhibitors, 0.91 (95% CI 0.41 to 2.00) for AT II antagonists, 1.16 (95% CI 0.95 to 1.41) for beta-blockers, and 0.77 (95% CI 0.63 to 0.95) for calcium channel blockers. Conclusions: Current long-term use of calcium channel blockers was associated with a significantly reduced risk of a Parkinson disease diagnosis, while the risk was not materially altered for users of angiotensin converting enzyme inhibitors or beta-blockers and, with less statistical precision, for users of angiotensin II antagonists. GLOSSARY: ACE = angiotensin converting enzyme; AD = Alzheimer disease; AT II = angiotensin II; BMI = body mass index; CHF = congestive heart failure; COMT = catechol-O-methyltransferase; COPD = chronic obstructive pulmonary disease; GP = general practitioner; GPRD = General Practice Research Database; IHD = ischemic heart disease; ISAC = Independent Scientific Advisory Committee; MHRA = Medicines and Healthcare products Regulatory Agency; OXMIS = Oxford Medical Information System; PD = Parkinson disease; TIA = transient ischemic attack.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
The Read clinical classification.
Chisholm, J. (1990) · BMJ · doi:10.1136/bmj.300.6732.1092 · Cited by 504
Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson’s disease
McNaught, K. S. P., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10512 · Cited by 203
Cited by
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Zamponi, G. W., Striessnig, J., Koschak, A., & Dolphin, A. C. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009654 · Cited by 1,103
Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1
Guzman, J. N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P. T., & Surmeier, D. J. (2010) · Nature · doi:10.1038/nature09536 · Cited by 843
Snow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J. D., Fung, V., Smith, R. A. J., Murphy, M. P., Taylor, K. M., & On behalf of the Protect Study Group (2010) · Movement Disorders · doi:10.1002/mds.23148 · Cited by 606
Metadata
- Authors
- Becker, C., Jick, S. S., & Meier, C. R.
- Venue
- Neurology
- Published
- 2008-04-15
- Volume
- 70
- Issue
- 16_part_2
- Pages
- 1438-1444
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2042861001
- Cited by
- 230
- References
- 3
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of antihypertensives and the risk of Parkinson disease. https://app.cochat.ai/papers/10.1212/01.wnl.0000303818.38960.44
- The paper
- Becker, C., Jick, S. S., & Meier, C. R. (2008). Use of antihypertensives and the risk of Parkinson disease. Neurology. https://doi.org/10.1212/01.wnl.0000303818.38960.44
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.